Xiaobo Wang

Background

About Xiaobo Wang

Accomplished Principal Scientist with extensive experience in biopharmaceutical sector conducting vivo / preclinical translational research. Earned reputation as an exceptionally self-motivated worker and independent thinker with a record of rapidly adopting and optimizing new techniques and concepts. Proven success establishing and performing productive and successful drug-delivery, sample collection methods, histopathological assessment, and developing and advancing clinical candidates from early lead selection to market approval. International leader in animal models, surgery, and drug delivery for the inner, middle, and outer ear across the most diverse range of species. Keen ability and demonstrated expertise in therapeutic areas including otic, laryngological, and neurological disorders. Main contributor to the development of OTIPRIO, an FDA approved drug for the treatment of bilateral effusive otitis media with pediatric myringotomy tube placement, and the treatment of acute otitis externa in patients 6 months of age and older. Key contributor to several Phase clinical candidates: Otividex for Meniere’s disease, OTO-313 for tinnitus, and OTO-413 for auditory neurodegeneration.